Cetera Investment Advisers Buys 10,385 Shares of DexCom, Inc. (NASDAQ:DXCM)

Cetera Investment Advisers increased its position in DexCom, Inc. (NASDAQ:DXCM) by 16.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 72,182 shares of the medical device company’s stock after acquiring an additional 10,385 shares during the quarter. Cetera Investment Advisers’ holdings in DexCom were worth $5,614,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of DXCM. Private Trust Co. NA grew its position in shares of DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 245 shares in the last quarter. Optiver Holding B.V. bought a new stake in DexCom during the fourth quarter valued at $33,000. TD Private Client Wealth LLC boosted its stake in DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock valued at $34,000 after buying an additional 167 shares during the period. Larson Financial Group LLC boosted its stake in DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after buying an additional 137 shares during the period. Finally, Heck Capital Advisors LLC bought a new stake in DexCom during the fourth quarter valued at $38,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Cfra Research raised DexCom to a “hold” rating in a report on Friday, March 21st. Robert W. Baird cut their price objective on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Friday, May 2nd. Wells Fargo & Company reissued an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Piper Sandler cut their price objective on DexCom from $100.00 to $90.00 and set an “overweight” rating for the company in a report on Friday, May 2nd. Finally, Morgan Stanley boosted their price objective on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a report on Friday, February 14th. Five analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $98.11.

Insider Activity at DexCom

In related news, COO Jacob Steven Leach sold 14,076 shares of the company’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $990,668.88. Following the completion of the transaction, the chief operating officer now owns 313,497 shares in the company, valued at $22,063,918.86. This represents a 4.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kevin R. Sayer sold 32,498 shares of the company’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $2,287,209.24. Following the transaction, the chief executive officer now owns 372,029 shares of the company’s stock, valued at approximately $26,183,401.02. This represents a 8.03% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 66,926 shares of company stock worth $4,734,384 over the last quarter. 0.32% of the stock is owned by corporate insiders.

DexCom Stock Performance

Shares of DXCM stock opened at $84.11 on Wednesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $132.26. The stock has a 50 day moving average price of $71.23 and a two-hundred day moving average price of $77.35. The company has a market capitalization of $32.98 billion, a P/E ratio of 58.82, a PEG ratio of 2.30 and a beta of 1.43.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. DexCom’s revenue was up 12.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.32 EPS. Analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.